research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
Search
for
Sort by
Research
480-510 / 1000+ results 
research Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata
Latanoprost works better for hair growth, and combining it with betamethasone valerate is most effective.
research Recurring Chemotherapy-Associated Alopecia Areata: Case Report and Literature Review
Chemotherapy may cause recurring hair loss due to an autoimmune response.
research Unusual forms of alopecia areata in a Trichology Unit
Less than a quarter of alopecia areata cases were unusual forms or had paradoxical regrowth.
research The effectiveness of mindfulness-based cognitive therapy for social anxiety symptoms in people living with alopecia areata: a single-group case-series design
Mindfulness-based cognitive therapy may reduce social anxiety and improve wellbeing in people with alopecia areata.
research Awareness, Beliefs, and Psychological Impact of Patients with Alopecia Areata in Saudi Arabia: A Multi-Center Study
Patients with alopecia areata in Saudi Arabia understand the condition's seriousness but still face significant psychological challenges.
research Alopecia universalis: A classical case report treated at Dr Batra’s® homeopathy clinic
Homeopathy helped regrow hair in a severe hair loss case.
research Efficacy of Trichloroacetic Acid in Patients with Alopecia Areata: A Clinico-Histopathological Study
Trichloroacetic acid is a safe and effective treatment for hair loss in alopecia areata patients.
research Drug Armamentarium for alopecia areata
No cure exists for alopecia areata, and treatments are personalized.
research The mystery of the disinterestedness regard Alopecia areata in Asians (especially Chinese men): A proposal of the use of a synthetic medicament plus a special herb from South America
A synthetic drug and a South American herb may help treat alopecia areata in Chinese men.
research Familial aggregation of alopecia areata
Alopecia areata, a common autoimmune hair loss condition, often runs in families.
research Alopecia areata
Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Epidemiology and burden of alopecia areata: a systematic review
Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.
research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
New treatments for Alopecia Areata show promise but need to be more effective and affordable.
research THE PATHOGENESIS OF ALOPECIA AREATA
Alopecia areata is likely caused by a combination of genetic factors and immune system dysfunction, and may represent different diseases with various causes.
research Effects of the Lexington LaserComb on hair regrowth in the C3H/HeJ mouse model of alopecia areata
The Lexington LaserComb helped regrow hair in mice with a condition similar to human hair loss.
research Large doses of glucocorticoid in the treatment of alopecia areata
Large doses of glucocorticoids are not suitable for general use in treating severe alopecia areata due to inconsistent results and risks.
research Treatment of Alopecia Areata With Tofacitinib
Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Eosinophils in fibrous tracts and near hair bulbs: A helpful diagnostic feature of alopecia areata
Finding eosinophils near hair bulbs helps diagnose alopecia areata.
research Factors Associated with Severity of Alopecia Areata
More research is needed to understand alopecia areata severity.
research Imbalance of T‐helper 17 and regulatory T cells in patients with alopecia areata
People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.
research Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures
The study found that immune responses disrupt hair growth cycles, causing hair loss in alopecia areata.
research The role of lymphocytes in the development and treatment of alopecia areata
Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
research The C3H/HeJ mouse and DEBR rat models for alopecia areata: review of preclinical drug screening approaches and results
Both mouse and rat models are effective for testing alopecia areata treatments.
research Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease‐associated psychological morbidity
Alopecia areata involves immune system imbalances that may lead to depression and anxiety.
research Type 1 interferon signature in the scalp lesions of alopecia areata
Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.